Cabaletta Bio banks $128.2M as warrant exercises land near expiry

What's the deal? Cabaletta Bio disclosed that holders exercised warrants from its June 2025 public offering, generating roughly $128.2 million in aggregate gross proceeds. The Philadelphia-based biopharmaceutical company detailed the outcome in a September 14, 2026 filing. The warrants expired on September 12, 2026.

How it played out: Cabaletta issued 53,090,190 warrants, each priced at $2.50 per share. Exercises came in two waves — 5,275,100 warrants through June 30, 2026, for about $13.2 million, then a rush of 46,011,900 warrants from July 1 to expiration for roughly $115.0 million.

Why now? The bulk of the capital arrived at the deadline. Nearly 90% of exercised warrants were converted in the final stretch before they lapsed, a common pattern as holders decide whether shares clear the strike price.

What's the endgame? The filing, signed by chief executive officer and president Steven Nichtberger, was made under Item 8.01 (Other Events). It carried no forward-looking statements or other business updates beyond the warrant details.

The signal: The raise ranks in roughly the 47th percentile by amount among comparable rounds — a mid-sized capital event rather than a headline financing. For Cabaletta, the fully realised warrant proceeds convert a 2025 offering into fresh cash without a new dilutive round.

Image credit: Generated with Gemini